참고문헌
- Bringuier PP, Umbas R, Schaafsma HE, et al (1993). Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res, 53, 3241-5.
- El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al (2009). Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol, 19, 1575-81. https://doi.org/10.1007/s00330-009-1340-7
- Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-403. https://doi.org/10.7314/APJCP.2014.15.6.2395
- Griffiths G, Hall R, Sylvester R, et al (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol, 29, 2171-7. https://doi.org/10.1200/JCO.2010.32.3139
- Huang HY, Shariat SF, Sun TT, et al (2007). Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol, 38, 1703-13. https://doi.org/10.1016/j.humpath.2007.04.003
- Ikeda M, Matsumoto K, Nishi M, et al (2014). Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. Asian Pac J Cancer Prev, 15, 6519-24. https://doi.org/10.7314/APJCP.2014.15.16.6519
- Kobayashi M, Matsumoto T, Ryuge S, et al (2012). CAXII Is a sero-diagnostic marker for lung cancer. PLoS One, 7, 33952. https://doi.org/10.1371/journal.pone.0033952
- Li SM, Zhang ZT, Chan S, et al (1999). Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol, 162, 931-5. https://doi.org/10.1097/00005392-199909010-00093
- Lu JJ, Kakehi Y, Takahashi T, et al (2000). Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res, 6, 3166-71.
- Matsumoto K, Satoh T, Irie A, et al (2008). Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology, 72, 444-9. https://doi.org/10.1016/j.urology.2007.11.128
- Matsumoto K, Shariat SF, Casella R, et al (2003). Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol, 170, 2248-52. https://doi.org/10.1097/01.ju.0000094189.93805.17
- Otunctemur A, Koklu I, Ozbek E, et al (2014). Are bladder neoplasms more aggresive in patients with a smoking-related second malignancy? Asian Pac J Cancer Prev, 15, 4025-8. https://doi.org/10.7314/APJCP.2014.15.9.4025
- Schwaibold HE, Sivalingam S, May F, Hartung R (2006). The value of a second transurethral resection for T1 bladder cancer. BJU Int, 97, 1199-201. https://doi.org/10.1111/j.1464-410X.2006.06144.x
- Takeuchi M, Sasaki S, Ito M, et al (2009). Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology, 251, 112-21. https://doi.org/10.1148/radiol.2511080873
- Wang HF and Wang JS (2012). Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer. Asian Pac J Cancer Prev, 13, 1723-6. https://doi.org/10.7314/APJCP.2012.13.5.1723
- Wu XR, Lin JH, Walz T, et al (1994). Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem, 269, 13716-24.
- Xu X, Sun TT, Gupta PK, et al (2001). Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer, 93, 216-21. https://doi.org/10.1002/cncr.9032
피인용 문헌
- Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis vol.36, pp.4, 2015, https://doi.org/10.2220/biomedres.36.253
- Comparative lipidomic study of urothelial cancer models: association with urothelial cancer cell invasiveness vol.12, pp.11, 2016, https://doi.org/10.1039/C6MB00477F
- Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer vol.18, pp.7, 2018, https://doi.org/10.1080/14737159.2018.1490179
- Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis vol.2018, pp.2314-6141, 2018, https://doi.org/10.1155/2018/8315410